

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Daniel G. Ericson *et al.*

Examiner: Patricia Bianco

Serial No.: 10/806,795

Group Art Unit: 3761

Filing Date: March 23, 2004

Docket No.: P-9006.04

Title: HEMOSTATIC SYSTEM AND COMPONENTS FOR EXTRACORPOREAL CIRCUIT

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8:** I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313-1450 on this 24 day of April, 2006.

Signature

Jo L. Brecht

Printed Name

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner of Patents and Trademarks  
U.S. Patent and Trademark Office  
Alexandria, VA 22313

Dear Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner for consideration in connection with the above-identified patent application.

Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of M.P.E.P. § 609, Applicants further request

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**Page 2**

Serial No. 10/806,795

Dkt.: P-9006.04

Filing Date: March 23, 2004


Title: HEMOSTATIC SYSTEM AND COMPONENTS FOR EXTRACORPOREAL CIRCUIT

that a copy of the Form 1449, initialed by the Examiner to indicate that all listed documents have been considered, be returned with the next Official Communication.

Applicants assert that nothing herein is intended to be construed as an admission as to whether a document constitutes prior art to the present application. Applicants reserve the right, pursuant to 37 C.F.R. §§ 1.31-1.132, or otherwise, to establish that the document(s) are not "prior art."

Respectfully submitted,

Date: April 18, 2006

By   
Katharine A. Jackson Huebsch  
Reg. No. 47,670  
Patent Attorney  
MEDTRONIC, INC.  
710 Medtronic Parkway  
Minneapolis, MN 55432  
Tel. 763.391.9634  
Fax. 763.391.9668  
Customer No. 27581

**INFORMATION  
DISCLOSURE  
STATEMENT**

Atty. Docket No.: P-9006.04

Serial No.: 10/806,795

Applicant(s): Ericson, et al.

Filing Date: 03-23-2004

Group: 3761

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	SubClass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	SubClass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)**

		Cosgrove, et al., "Aprotinin Therapy for Reoperative Myocardial Revascularization: A Placebo-Controlled Study," <i>Ann. Thorac. Surg.</i> 54:1031-1038 (1992).
		Levy, et al., "A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting," <i>Circulation</i> , 92(8):2236-44 (1995).
		Bennett-Gurreo, et al., "ε-Aminocaproic Acid Administration and Stroke Following Coronary Artery Bypass Graft Surgery," <i>Ann. Thorac. Surg.</i> 67:1283-1287 (1999).

**EXAMINER****Date Considered**

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

